poisar

Stocks · News reference

Wealthfront, Orchestra Biomed, AeroVironment And Other Big Stocks Moving Higher On Thursday

BenzingaAvi Kapoor

U.S. stocks fell, but Wealthfront surged 6.6% after beating Q2 earnings and revenue estimates; Orchestra Biomed, Clover Health and AeroVironment also rose.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Zacks Investment ResearchNa

    ONDS Raises 2026 Outlook as Backlog and Defense Demand Accelerate

    Ondas Inc. (ONDS) raised its 2026 revenue guidance to at least $550M following Q3 revenues of $167.5M, up 16-fold year-over-year. The company expects Q4 revenues exceeding $250M, supported by an $835M backlog and $214M in new orders. However, adjusted gross margins declined to 34.8% and adjusted EBITDA losses widened to $59.7M, signaling profitability challenges despite strong top-line growth.

  2. Zacks Investment ResearchNa

    Is ONDS Worth Buying as Hypergrowth Battles Margins and M&A Risks

    Ondas Holdings (ONDS) targets $550M in 2026 revenues and $1.1B in 2027 with organic growth above 40%, backed by an $835M backlog. However, the company faces widening EBITDA losses, rising costs, and M&A integration challenges. Analysts recommend a hold-and-watch approach pending evidence of operating leverage and profitability.

  3. Zacks Investment ResearchNa

    Should You Buy, Hold or Sell Ondas Stock Post-Q3 Earnings?

    Ondas Inc. (ONDS) reported Q3 2026 revenues of $167.5 million with an $835 million backlog, raising 2026 guidance to $550 million and 2027 target to $1.1 billion. However, the stock fell 17.8% post-earnings due to widening EBITDA losses ($59.7 million), gross margin compression (21.8%), and significant cash burn ($278 million in nine months). While the company benefits from strong defense demand and acquisition-driven growth, execution risks and profitability challenges warrant caution.